Shots:

• The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field of rheumatology- gastroenterology and dermatology
• Sandoz Canada has completed the pCPA negotiations for Hyrimoz- which is the first step in securing public reimbursement
• Hyrimoz is a fully human TNF blocker and is available in 40 mg/0.8 mL & 20 mg/0.4mL in a prefilled syringe- 40 mg/0.8 mL in autoinjector in SensoReady Pen autoinjector designed for patients with limited dexterity

 ­ Ref: Sandoz | Image: Sandoz